For people with HIV and fatty liver on INSTI drugs, tesamorelin reduced liver fat by 31% compared to their starting point, which was a significant improvement. This finding is from the abstract summary - full study details were not available

For people with HIV and fatty liver on INSTI drugs, tesamorelin lowered liver fat by 4.9% compared to almost no change (0.1%) in the placebo group, which was a significant difference. This finding is from the abstract summary - full study details were not available

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 31% compared to their starting point, which is much better than the tiny change seen in those on a placebo.

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 4.9% compared to a tiny 0.1% reduction in those on a placebo.

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.